Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: 2025 Eurostat Trade Data and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: 2025 Eurostat Trade Data and Economic Impact
Clinical Trials in China / NCT07277686
Recruiting Observational

AI Facial Analysis Algorithm to Screening Coronary Artery Disease in High-Risk Community Population

NCT07277686 · tracked via the Priya Life Science China tracker
Sponsor
China National Center for Cardiovascular Diseases
Phase
Observational
Started
2025-12-11
Last updated
2026-01-06

Condition(s) studied

Coronary Artery Disease (CAD)Artificial Intelligence AlgorithmsFaceScreening

Investigational drug(s) / intervention(s)

No Intervention

No Intervention: No Intervention

Study summary

This study aims to evaluate the effectiveness of this facial image-based AI algorithm for screening CAD in high-risk community populations (specifically individuals with diabetes, hypertension, or aged over 65). The main objectives are:

1. To verify if the AI algorithm can accurately distinguish between high-risk and low-risk groups by comparing the actual prevalence of CAD in these groups.
2. To compare the CAD detection rate using this AI screening strategy against the natural detection rate in a real-world cohort.

Eligibility

Sex
ALL
Min age
18 Years
Max age
—
Healthy volunteers
Accepted
Inclusion Criteria: * Age \>= 18 years. * Community high-risk population, defined as individuals meeting at least one of the following criteria: 1. Diagnosed with Diabetes Mellitus; 2. Diagnosed with Hypertension; 3. Advanced age (\> 65 years old). Exclusion Criteria: * Prior confirmed diagnosis of Coronary Heart Disease (CAD), including clinically diagnosed CAD, history of Coronary Artery Bypass Grafting (CABG), or history of Percutaneous Coronary Intervention (PCI). * History of diagnosed Heart Failure. * Significant facial alterations or conditions that may interfere with AI image analysis, such as plastic surgery, severe facial trauma, or heavy makeup. * Refusal to participate in the study.

Primary outcome measure(s)

  • Difference in Prevalence of CAD Between AI-Stratified High-Risk and Low-Risk Groups — Up to 6 months
    Participants in the diagnostic test cohort are stratified into high-risk and low-risk groups using the AI screening strategy. Subsequently, all participants undergo Coronary Computed Tomography Angiography (CCTA). This outcome measures the difference in CAD prevalence between the two groups based on CCTA results.

Trial sites (3)

FacilityCityRegionStatus
Zhoukou Chuanhui District Hospital of Traditional Chinese Medicine Zhoukou Henan Recruiting
Zhoukou Specialized Disease Hospital Zhoukou Henan Recruiting
Fuwai Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College Beijing China Not Yet Recruiting

More China National Center for Cardiovascular Diseases trials in China

rhBNP for Prevention of Cardiac Surgery-Associated Acute Kidney Injury (CSA-AKI) Starting soon
Effectiveness of an AI-Enabled Stratified Management System for Premature Coronary Artery Disease Recruiting
An Observational Study of Subcutaneous Implantable Cardioverter Defibrillator in Patients with Hypertrophic Cardiomyopathy At High Risk of Sudden Cardiac Death Active, not recruiting
The Chinese Hypertrophic Cardiomyopathy Study(CHCS) Recruiting
Concomitant Hybrid Versus Catheter Ablation for Atrial Fibrillation With Hypertrophic Cardiomyopathy Recruiting

Other trials for the same condition

Optimization and Validation of Quality Control Indicators for Coronary Revascularization Based on Antiplatelet Therapy Starting soon
Micro-axial Flow Pump-Supported PCI in Complex Coronary Artery Disease With Ischemic LV Dysfunction Starting soon
Desflurane Potentially Induces Postoperative Cognitive Dysfunction in Elderly Patients Undergoing Perioperative Procedures by Modulating Cdc42 and Clock Proteins Starting soon
The Correlation Between Obstructive Sleep Apnea-Related Nocturnal Hypoxemia Parameters and Coronary Microvascular Dysfunction: A Prospective Cohort Study (SLEEP-CMD) Starting soon
"Xijiang Project" Screening Cohort for NPC Recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07277686 on ClinicalTrials.gov ↗ ← All trials in China